Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Gilead Sciences, Inc.NASDAQ: GILD

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents falls 38.2% from a year ago

Cash & equivalents stood at $3.18B at the end of Q2 FY2026, down 38.2% from a year earlier and down 58.3% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.

Context

  • Cash & equivalents amounted to 6.4% of total assets at the end of Q2 FY2026, down 2.8 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -38.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.18B-58.3% QoQ
Last fiscal yearDec 2025
$7.56B-24.3% YoY
Year agoJun 2025
$5.14B-38.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-38.2%——
1 year-24.3%——
3-year CAGR+11.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
7.56B USD
Year-over-year change
-24.3%
4-year CAGR
+9.1%

Cash & Equivalents vs competitors

How GILD compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -38.2% is the 8th highest of 10, against a peer median of -7.2%.
  • Cash & equivalents amounts to 6.4% of total assets for GILD, versus a peer median of 5.3%.
GILD Competitors
Cash & Equivalents for GILD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JNJJohnson & JohnsonSep 2026$16.91B USD-7.2%+15.2%8.6%
LLYEli Lilly and CompanyJun 2026$8.89B USD+163.3%+51.3%6.2%
AZNAstraZeneca PLCSep 2026$7.92B USD-2.7%-2.5%6.6%
NVSNovartis AGJun 2026$7.62B USD+14.4%+15.0%6.2%
MRKMerck & Co., Inc.Jun 2026$6.85B USD-14.5%+4.7%5.3%
ABBVAbbVie Inc.Jun 2026$6.57B USD+1.6%-17.2%4.9%
SNYSanofiJun 2026€6.35B EUR-58.7%-15.6%4.9%
GILDGilead Sciences, Inc.Jun 2026$3.18B USD-38.2%+11.8%6.4%
GSKGSK plcJun 2026£3.09B GBP-37.4%-3.1%5.0%
PFEPfizer Inc.Jun 2026$976M USD-40.4%+40.0%0.5%
Peer median (excluding GILD) —-7.2%+4.7%5.3%

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents5.34B5.41B6.09B9.99B7.56B
Short-term Investments1.18B973M1.18B1.58B2.05B
Net Receivables4.49B4.78B4.66B4.42B4.91B
Inventory1.62B1.51B1.79B1.71B1.77B
Other Current Assets002.37B995M1.14B
Total Current Assets14.77B14.44B16.09B19.17B18.34B
Property, Plant & Equipment (Net)5.12B5.48B5.32B5.41B5.61B
Goodwill8.33B8.31B8.31B8.31B8.31B
Intangible Assets33.46B28.89B26.45B19.95B16.98B
Long-term Investments1.31B1.25B1.16B02.97B
Tax Assets0002.38B1.96B
Other Non-current Assets4.96B4.8B4.79B3.77B4.85B
Total Non-current Assets53.18B48.73B46.04B39.82B40.68B
Total Assets67.95B63.17B62.13B59B59.02B
Account Payables705M905M550M833M715M
Short-term Debt1.52B2.27B1.8B1.82B2.81B
Tax Payables539M959M1.21B830M0
Deferred Revenue00000
Other Current Liabilities1.43B3.62B3.92B3.82B3.86B
Total Current Liabilities11.61B11.24B11.28B12B11.81B
Long-term Debt25.18B22.96B23.19B24.9B22.13B
Deferred Tax Liabilities4.36B2.67B1.59B724M402M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities5.74B5.09B3.32B2.13B2.06B
Total Non-current Liabilities35.28B30.72B28.1B27.75B24.59B
Total Liabilities46.89B41.96B39.38B39.75B36.41B
Common Stock1M1M1M1M1M
Retained Earnings16.32B15.69B16.3B11.5B13.73B
Accumulated OCI83M2M28M132M39M
Other Stockholders Equity00000
Minority Interest(5M)(31M)(84M)(84M)(84M)
Total Equity21.06B21.21B22.75B19.25B22.62B
Total Debt26.7B25.23B24.99B26.71B24.94B
Net Debt21.36B19.82B18.9B16.72B17.37B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.